2022 Volume 9 Issue 2 Pages 33-41
Purpose: The "NAD World" (proposed by Professor Shin-Ichiro Imai of the University of Washington), in which the control of aging, lifespan, and metabolism is systemically integrated through NAD (nicotinamide adenine dinucleotide), has attracted worldwide attention and is being studied from various angles, however, there are few reports of clinical studies in humans. In this study, we investigate the changes in various biomarkers in humans after oral intake of nicotinamide mononucleotide (NMN), a precursor of NAD, and evaluate its clinical significance. Methods: Based on the approval to start the study at the ethics review, 17 postmenopausal women (mean age 55.0 years) without underlying diseases who agreed to participate in the study were subjects and received oral intake of 300 mg/day of pure NMN for eight weeks. The examination items included body measurements, basal metabolic rate, blood pressure, grip strength, glycation level (AF value), blood biochemical tests, various hormones, blood SIRT1 mRNA expression and NMN, NAD and NAM levels, immunological tests (aging, T cell subset including exhausted cells), and skin VAS (visual analog scale). Results were statistically analyzed and compared at zero and eight weeks (blood biochemistry tests were performed at four weeks to confirm safety). In addition, we asked the patients to keep a diary during the course of the study to monitor their NMN intake, their bodily sensation, and side effects. Results: One of the 17 subjects dropped out at the end of four weeks due to persistent mild headache. The results showed significant changes in NAM (nicotinamide/vitamin B3) from 45.2 to 164.7 (p < 0.001), adiponectin from 13.6 to 16.2 (p = 0.004), and skin VAS score (6/7 items, p < 0.001 to = 0.001) before and after intake. Significant differences were also observed for BMI, AF levels, platelets, HbA1c, HDL-C, amylase, DHEA-s, NAD, and narrowly defined regulatory T cells (p < 0.05 above). In addition, all subjects showed a positive bodily sensation with skin, sleep, and fatigue. There were no problems with subjective symptoms or laboratory data in the 16 who completed the study. Conclusion: NMN 300 mg/day orally for eight weeks showed no safety issues and favorable changes in many biomarkers, suggesting that NMN, a member of the NAD world, may be a promising nutritional material for aging and metabolic control in humans.
